in evaluating HBV disease progression and in deciding on treatment strategies. [2] [3] [4] Therefore, early and accurate diagnosis of liver inflammation and fibrosis could benefit patients with HBV infection.
Liver biopsy with histopathology is the gold standard for diagnosing liver disease. However, liver biopsy is invasive and is coupled with the risk of bleeding or anesthetic complications and of fibrosis stage misclassification due to sampling errors. Staging fibrosis and inflammation using noninvasive methods have been designed to overcome the disadvantages and inconveniences of liver biopsy. [5] [6] [7] Clinical practice needs a simple operation or a noninvasive and easy way to diagnose liver inflammation, injury, or fibrosis. 7 Serologic tests and FibroScan have been recommended by the World Health Organization (WHO)
as noninvasive tests for CHB patients. 8 However, FibroScan is costly and has been shown to be unfavorable in patients with ascites. 9 Serum markers have been proposed to evaluate liver disease including alanine aminotransferase (ALT), the aspartate aminotransferase (AST)-toplatelet ratio index (APRI), the fibrosis index based on the four factors (FIB-4), the red cell volume distribution width (RDW)-to-platelet ratio
(RPR), and the gamma-glutamyl transpeptidase (GGT)-to-platelet ratio (GPR).
Alanine aminotransferase is the most common serum marker for evaluating liver injury. Recently, however, the role of ALT in predicting liver inflammation has been questioned. Some patients with moderate liver disease identified on histology can have a normal-level ALT. 10, 11 Studies showed that even when patients have a normal ALT, they can still have a significantly increased risk of liver disease or progression of liver disease. 12 Increasingly, researchers focus on finding accurate formulas for predicting liver inflammation and fibrosis by combining laboratory tests. APRI and FIB-4 have been used extensively to diagnose HBV-related disease. The World Health Organization (WHO) recommended FIB-4 and APRI as noninvasive tests for CHB patients.
However, the sensitivity and specificity of these calculations are still controversial. 13, 14 Recently, Lemoine et al proposed that GPR was a new and more accurate index than APRI or FIB-4, which was supported by another study on a population of Chinese subjects. 15, 16 In contrast, another group determined that GPR was not superior to APRI or FIB-4.
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More research is necessary to determine whether GPR is better than APRI or FIB-4 in diagnosing HBV-related liver diseases. Chen et al 18 proposed that RPR was superior to APRI and FIB-4; however, in another study, the area under receiver-operating characteristic curves (AUROC) was similar to FIB-4 and APRI for diagnosing significant fibrosis.
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In addition, our previous studies focused on the genetic factors and the immune regulatory factors in patients with chronic infection. The association between immune cells and serum markers was found in our studies. [20] [21] [22] Here, we are concerned about how serum markers represented the degree of inflammation in liver. Although numerous studies have attempted to compare different formulas in diagnosing fibrosis in patients with CHB, the studies on evaluating the application of APRI, FIB-4, GPR, and RPR in diagnosing HBV-related inflammation and fibrosis are still limited. The aim of our study was to evaluate the clinical significance of the above four formulas in diagnosing liver inflammation and fibrosis in patients with CHB. 
| MATERIALS AND METHODS

| Patients
| Liver biopsy
Liver biopsies were performed as described elsewhere.
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Histological grading of inflammation (G0-G4) and staging of liver fibrosis (S0-S4) were carried out following the Scheuer scoring system. 7 None to mild inflammation was defined as G 0-1; moderate inflammation was defined as G = 2; and severe inflammation was defined as G = 3. Patients with significant fibrosis were defined as S = 2; severe fibrosis was defined as S = 3; and early cirrhosis was defined as S = 4.
| Serological tests
All patients had routine laboratory blood tests at the time of biopsy and based on manufacturer's instructions. Serum markers included ALT, AST, GGT, albumin (ALB), and glucose (GLU) were determined by auto-analyzer (Roche, Germany). Blood routine test was performed using an automated hematology analyzer (Sysmex, Japan). Serological markers (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc) were measured using commercially available kits (Roche, Germany). HBV-DNA was measured using the real-time polymerase chain reaction assay (Roche, Germany). 
| Statistical analyses
The diagnostic performances of APRI, FIB-4, RPR, GPR, ALT, and
GGT to diagnose liver inflammation and fibrosis were estimated by the ROC curve, and optimal cut-offs were determined using Youden's index. The AUROC, sensitivity, and specificity of each noninvasive test were analyzed using SPSS software (version 23.0); ROC curves were compared using MedCalc (version 11.4).
| RESULTS
| Baseline characteristics of patients
Three hundred twenty-three CHB patients were enrolled in our study between June 2015 and December 2016. Of the 323 patients, the majority of patients had minimal histological changes on liver biopsy.
Only 87 (27%) patients had moderate to severe inflammation (G ≥ 2), and 70 (21.7%) patients had significant to severe fibrosis (S ≥ 2). The majority of patients enrolled were male (65.3%) and HBeAg negative (58.8%). The median age for G 0-1, G 2-3, S 0-1, and S 2-4 were 34, 39, 35, and 39 years, respectively (Table 1) .
Laboratory test results for the different groups are shown in Table 1 . In general, compared with patients with G 0-1 inflammation, those with G ≥ 2 inflammation had higher ALT and GGT levels but lower platelet (PLT) counts. Higher levels of ALT and GGT and lower PLT counts were also observed in patients with S ≥ 2 fibrosis (Table 1) .
| Correlations between serum markers or formulas and liver inflammation grades
Spearman's correlation analysis was performed to evaluate the cor- Of the patients with normal ALT levels (ALT < 40 IU/L), 31 (18.7%) of 166 patients had moderate to severe liver inflammation.
In addition, 60 (24.2%) patients with G ≥ 2 had an ALT level less than 80 IU/L.
The Kruskal-Wallis test showed that the markers mentioned above were significantly increased from G 0-1 to G 3. GGT increased almost two-fold in patients with severe inflammation (G = 3) over patients with none or mild inflammation. Multivariable analyses identified GGT (OR = 1.031, 95% CI = 1.015-1.048; P < .05) and PLT (OR = 0.986, 95% CI = 0.980-0.993; P < .05) as independent predictors of moderate to severe liver inflammation.
Interestingly, scores for predicting fibrosis, GPR and APRI, were also much higher in patients with G3 inflammation compared with patients with G0-1 inflammation ( Figure 1A , B).
| Correlations between serum markers or formulas and liver fibrosis stages
Spearman's correlation analysis showed that ALT (rs = 0.168, P < .05), AST (rs = 0.234, P < .05), GGT (rs = 0.246, P < .05), and PLT (rs = -0.220, P < .05) were correlated with fibrosis stages.
Multivariable analysis showed GGT (OR = 1.027, 95% CI = 1.012-1.043; P < .05) and PLT (OR = 0.986, 95% CI = 0.979-0.993; P < .05)
were independent predictors of significant to severe fibrosis.
Compared with S0-1 patients, those with significant fibrosis to early cirrhosis (S ≥ 3) had higher FIB-4, APRI, GPR, and RPR scores.
The four markers increased with fibrosis progression. In other words, higher index scores were seen with increasing fibrosis stages ( Figure 1C ).
| Performances of FIB-4, APRI, GPR, and RPR for the diagnosis of liver inflammation
Alanine aminotransferase is the one of the most commonly used measures of liver inflammation. GGT is considered as an independent predictor of moderate to severe liver inflammation. FIB-4, APRI, GPR, and RPR are noninvasive markers used in the diagnosis of liver fibrosis. We compared these indexes to assess their ability to correctly diagnosis liver inflammation.
All indexes could predict liver inflammation. The optimal cut-off value was determined by Youden's index. The AUROCs, sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), positive likelihood ratios (PLR), and negative likelihood ratios (NLR) are summarized in Table 2 and Figure 2 . Among those markers, AUROCs of GPR and APRI were superior to those of FIB-4, RPR, ALT, and GGT in predicting liver inflammation.
| Performance of FIB-4, APRI, GPR, and RPR for diagnosing moderate or severe fibrosis in CHB patients
To diagnose S ≥ 2 liver fibrosis, the AUROCs were 0.683 for FIB-4, 0.727 for APRI, 0.711 for GPR, and 0.686 for RPR. However, the AUROC differences among all the markers were not significant. The (Table 3 and Figure 3 ).
Using cut-off value of FIB-4 (1.45), recommended by WHO, for predicting significant to advance fibrosis, the sensitivity (8.70%) was lower but with higher specificity (95.5%). In our study, the optimal 
| DISCUSSION
In our study, we validated the performance of FIB-4, APRI, GPR, and RPR in diagnosing liver inflammation and fibrosis. We showed that these markers are potentially useful in predicting liver inflammation and fibrosis. APRI and GPR might be useful in diagnosing HBV-related liver diseases. No significant differences were seen in the performance of APRI, GPR, FIB-4, and RPR to diagnose S ≥ 2 liver fibrosis, but APRI and GPR were superior to the other markers in diagnosing S ≥ 3 liver fibrosis and in diagnosing G ≥ 2 and G ≥ 3 liver inflammation.
The risk of developing HCC is higher in patients with chronic hepatitis, 29 and therefore, it is important to identify patients with liver inflammation and fibrosis so that treatment and HCC surveillance can be started. ALT has been used as a reliable marker for liver inflammation 30 ; GGT has also been used for the diagnosis of HBV-related inflammation. However, ALT is not always increased when liver inflammation is present. [31] [32] [33] Michelle et al showed that patients with an HBV-DNA > 10 000 copies/mL, age > 40 years, and ALT > 25 IU/L had an increased risk for HBV-related liver disease progression. 34 Our study found that both ALT and GGT increased gradually from G0 to G3. Nevertheless, some patients with normal ALT levels (ALT ≤ 40 IU/L) had moderate to severe liver inflammation. When patients had an ALT < 80 IU/L, 24.2% had histological changes in the liver biopsies, and a small proportion of CHB patients had normal ALT with chronic liver inflammation. Using ALT alone is likely not enough to predict disease progression. In addition, the AUROCs of ALT and GGT for predicting G ≥ 2 were only 0.671 and 0.654, respectively. We found the optimal cut-off value of ALT for a G ≥ 2 APRI, aspartate transaminase to platelet ratio index; FIB-4, fibrosis index based on the 4 factors; GPR, gamma-glutamyl transpeptidase to platelet ratio index; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; RPR, red cell volume distribution width-to-platelet ratio.
F I G U R E 2 ROC curves of fibrosis scores (APRI, FIB-4, GPR, and RPR) for diagnosing S ≥ 2 GRP, and RPR) related to GGT serum levels and PLT counts should be followed in patients with CHB, especially when the GGT or PLT counts persistently change.
GPR was calculated by GGT and PLT and first be reported in 2015.
It was considered a novel and accurate index for liver fibrosis diagnosis compared with APRI and FIB-4 in West Africa, but lower AUROCs in Chinese CHB patients. 16, 35 We showed that GPR could be used to not only diagnose different stages of fibrosis but could also diagnosis different grades of inflammation. The AUROC of GPR was much higher than that of GGT and ALT in patients with G ≥ 2 inflammation, and using a cut-off value of 0.44, the sensitivity and specificity were 48.6% and 84.9%, respectively. Moreover, the AUROC increased to even more when GPR was used to diagnose G ≥ 3 inflammation. In these cases, the sensitivity was 80.0% when we chose 0.48 as the optimal cut-off value. To predict the stages of liver fibrosis in CHB patients, GPR was comparable with other indexes in the diagnosis of S ≥ 2 fibrosis. However, the AUROC of GPR was significantly higher than that of FIB-4 and RPR in the diagnosis of S ≥ 3 fibrosis. The cutoff values of GPR in our study (0.217 for S ≥ 2; 0.374 for S ≥ 3) were similar to a study by Lemoine et al 16 (0.32 for S ≥ 2; 0.32 for S ≥ 3).
Nevertheless, the cut-off values in another Chinese study (0.61 for S ≥ 2; 0.65 for S ≥ 3) were higher than in our study. 35 The cut-off value of GPR was 0.217 to diagnose S ≥ 2 fibrosis, and the corresponding sensitivity, specificity, PPV, and NPV were 86.5%, 44.7%, 27.3%, and 93.3%, respectively. Evidently, GPR is likely useful at excluding moderate to severe liver inflammation and fibrosis.
Since APRI and FIB-4 were successfully used in to diagnose patients with HCV, 6, 26 APRI, aspartate transaminase to platelet ratio index; FIB-4, fibrosis index based on the 4 factors; GPR, gamma-glutamyl transpeptidase to platelet ratio index; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; RPR, red cell volume distribution width-to-platelet ratio.
F I G U R E 3 ROC curves of fibrosis scores (APRI, FIB-4, GPR, and RPR) for diagnosing S ≥ 3 had a lower diagnostic accuracy than FIB-4 through meta-analysis. 36, 37 Our results indicated that the two formulas had similar diagnostic accuracy in predicting S ≥ 2 fibrosis, while APRI was superior to FIB-4 in predicting S ≥ 3 fibrosis. The optimal cut-off value of APRI for diagnosis of significant fibrosis was 0.52, which was much closer to the low cut-off value recommended by WHO (0.5 for significant fibrosis). With a cut-off value of 0.52 for the diagnosis S ≥ 2 fibrosis, the sensitivity and specificity were 80.8% and 52.8%. Another cut-off value recommended by WHO was 1.5 for the diagnosis of S ≥ 2 fibrosis, which would result in a higher specificity and lower specificity results. In our cohort, changing the cut-off value to 1.5 increased the specificity to 94.9%. We also found that APRI might be helpful in the diagnosis of liver inflammation; the AUROCs of APRI were 0.732 for G ≥ 2 and 0.861 for G ≥ 3 inflammation. Especially with the cut-off value of 0.84 for diagnosis G ≥ 3 inflammation, the sensitivity and specificity were significantly higher than those of ALT and FIB-4. could also be used for diagnosis of inflammation; however, its performance was no better than that of the other indexes. Although the RPR was similar to the FIB-4, researchers proposed a RPR-HBV DNA algorithm to improve the diagnostic accuracy of the RPR for liver fibrosis. Therefore, a more accurate system for diagnosis of liver fibrosis could create by combining markers of liver disease.
The discrepancies among the four markers for the diagnosis of liver diseases could be due to the heterogeneity of patients enrolled, the prevalence of liver fibrosis stages, the different scoring systems used in pathological diagnosis of liver diseases, and genetic factors.
However, our study still has several limitations. First, our study included a small number of patients with S3-4 and G3, which might not be enough to develop a novel predictive model for diagnosing liver inflammation and fibrosis. Second, our study was retrospective and patients were recruited from a single-center, in which some selection bias could exist. Third, until now it has been demonstrated that liver stiffness measured by transient elastography (TE) or FibroScan could be used as a reliable marker for liver fibrosis diagnosis. Although
FibroScan is not suitable for application in patients with ascites and elevated aminotransferase levels, the AUROCs for diagnosis of fibrosis were much higher than the serum markers. 9,38,39 However, since there was insufficient information from the FibroScan, we did not make an analyze of FibroScan performance in diagnosis of liver fibrosis. In the future, we plan to expand the number of patients enrolled and develop a more accurate model for diagnosis liver inflammation and fibrosis by combining serum markers and FibroScan results. Furthermore, we will also verify the significance of serum markers dynamic change in liver diseases progression and regression.
In conclusion, our study showed that serum ALT is not robust enough to diagnose liver inflammation on its own. APRI and GPR appear to be better markers to diagnose HBV-related liver inflammation and fibrosis. No difference of FIB-4, APRI, GPR, and RPR to predict patients with S ≥ 2 fibrosis was observed. GPR and APRI were superior to RPR and FIB-4 in being able to identify patients with S ≥ 3 fibrosis and patients with G ≥ 2 and G ≥ 3 inflammation. From this study, it appears that currently, the GPR and the APRI might be the most useful markers to monitor liver disease progression and to decide on treatment in patients with CHB.
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